Search companies

Live

Tuesday, 17 November 2026 · 583 Summaries Today

S&P/ASX 200 · 8,883.20 (-1.79%)

Elixir Reports 79% Improvement In Lorelle-3H Flow, But Well Obstruction Halts Testing

EXR: $0.059 +3.51% · MC: $120M

After a 60-day soak, Lorelle-3H’s equivalent 12-hour flow rates improved 79% from the first testing phase, while stimulation-fluid flowback fell 85%; testing is paused as Elixir mobilises equipment to clear a debris blockage. Elixir also received its approximately $12 million R&D refund and repaid its R&D debt facility, leaving a net cash inflow of approximately $2 million.

Source announcements: 2026-11-02 08:23 to 2026-11-02 08:23 Sydney time
Story updated 2026-11-02 08:47 Sydney time
SourcesL3H Update & R&D Refund of $12.1m Received
Comments